Form 4: Rani Therapeutics Director Amends Stock Option Prices

Rani Therapeutics director Jean-Luc Butel amended the exercise prices of several stock options on December 16, 2024.

Summary

• On December 16, 2024, Jean-Luc Butel, a director at Rani Therapeutics, amended the exercise prices of several stock options.
• The exercise price of one set of options for 101,276 shares was increased from $2.84 to $4.11 per share.
• Another set of options for 18,875 shares had their exercise price increased from $2.84 to $9.44 per share.
• There were no changes to the expiration dates or vesting schedules of these options.
• The options were originally granted with a vesting schedule of 1/3rd vesting on April 20, 2022, and 1/36th vesting monthly over the following two years.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock option amendments, with no inherent positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing related to changes in beneficial ownership of securities by a company insider, which is common in the biotech industry.

Comparison to Industry Standards

• Stock option grants and amendments are common practices in publicly traded companies, especially in the biotech sector, to incentivize and retain key personnel.
• The specific exercise prices and vesting schedules are unique to Rani Therapeutics and its agreements with its directors.
• Comparable companies would have similar filings when directors or officers have changes to their stock option holdings.

Stakeholder Impact

• The changes in stock option prices may have a minor impact on the potential dilution of existing shareholders if the options are exercised in the future.

Key Dates

Keywords

stock options, exercise price, Rani Therapeutics, director, Jean-Luc Butel, amendment, vesting schedule